Chief Commercial Officer — Patient-Access Organisation

The mandate

A patient-access organisation has won demand faster than its provider network and navigation capacity have matured. Payer agreements contain different response promises, providers publish availability inconsistently and referral teams absorb the mismatch through manual negotiation. The current commercial leader is departing. An urgent replacement CCO must make every growth commitment operable before pursuing further volume.

Approximately 550 employees and material partners support payer relationships, provider contracting, referrals, scheduling, navigation, analytics and service operations from Zurich across the wider region. The CCO owns commercial strategy, payer and provider partnerships, pricing, contracting, growth and commercial operations, reporting to the Group Chief Executive or nominated sponsor. Clinical acceptance and patient prioritisation remain professionally governed.

The first task is a promise inventory. Every contract will be mapped by population, pathway, access window, reporting, language, geography and exception. The CCO will identify provisions that operations cannot reliably deliver or that rely on unpriced manual work. Renewal and remediation decisions should occur before service failure becomes a relationship crisis.

Provider capacity needs commercial evidence. A contracted specialist is not capacity unless appointment supply, acceptance criteria, location and response are current. The CCO will establish provider availability standards and consequence for repeated mismatch. Commercial teams must stop selling a network based on directory size when usable access is materially smaller.

Referral demand will be segmented by clinical and operating need. Urgent, complex, routine and preference-sensitive pathways consume navigation differently. Pricing and service design should recognise incomplete referrals, authorisation, translation and coordination. Average handling cost cannot support a contract with disproportionate exception burden.

Payer relationships will move from broad satisfaction to joint operating truth. Reviews should show eligible demand, accepted referrals, wait, unsuccessful placement, patient communication and cause. The CCO will negotiate shared actions where payer authorisation or benefit design obstructs access rather than allowing the provider organisation to own every delay.

Growth must follow constrained capacity. Campaigns and new contracts require evidence of provider supply and navigation skills. The CCO will use staged populations, caps or launch gates where needed. A commercial target does not authorise teams to queue patients beyond a clinically or contractually acceptable point.

Pricing will reflect complexity and value. The organisation may use per-member, case, subscription or performance-linked structures. The CCO will model utilisation, exception, provider and data costs, with risk corridors for uncertain demand. Discounts need an explicit exchange and duration; permanent price leakage cannot be called market entry.

Provider terms must protect independence. Payment and volume arrangements cannot encourage unnecessary care or inappropriate prioritisation. The CCO will work with clinical and compliance leaders on fair-market-value, conflict and referral controls. High demand will not excuse a provider's repeated quality or communication failures.

Commercial data and attribution need repair. Pipeline stages, contracted lives, referrals and completed placements are conflated. The CCO will establish definitions and reconcile sales claims to operational delivery and collection. Account incentives will include contract quality, access and retention, not signature value alone.

Cross-border and multilingual growth requires local truth. Provider regulation, patient rights, reimbursement and language differ. The Zurich team will set common commercial discipline while using country specialists to validate propositions. A standard contract shell must not flatten mandatory local requirements.

Customer communication is part of commercial integrity. Patients should understand the organisation's role, expected timing, charges and alternatives. Payer branding must not obscure who holds clinical responsibility. Complaints about promise or affordability will reach account leaders and influence renewal economics.

The replacement CCO will rebuild the leadership team around payer, provider and commercial-operations capability. Relationship history should transfer before the incumbent leaves. No priority account or provider cluster should depend solely on one executive's personal access.

What you will own

• Payer, provider and growth strategy.
• Contract promise inventory and remediation.
• Capacity-backed propositions and launch gates.
• Pricing, risk corridors and pathway economics.
• Provider commercial standards and conflict controls.
• Pipeline, attribution and incentive integrity.
• Cross-border commercial operating model.
• Commercial succession and relationship transfer.

The first 12 months

Within 30 days, review priority contracts and provider capacity, identify undeliverable promises and protect affected patient pathways. Reconcile the commercial pipeline to operational readiness.

By month five, reprice or remediate material exceptions, introduce provider availability standards and implement capacity gates for new business. Complete key relationship handovers.

At twelve months, improve contribution on renewed contracts by 300 basis points, reduce unpriced manual exceptions by 50% and increase referrals placed within agreed access windows by 25%. At least 95% of marketed provider capacity must be recently verified, while no material payer relationship depends on a single commercial owner.

What the sponsor will examine

• Contract promises connected to operating capacity.
• Provider directories reflecting usable access.
• Complex referrals priced with their true burden.
• Growth paused before patient queues become unsafe.
• Incentives rewarding delivered contract quality.
• Relationships institutionalised beyond individuals.

The person

You bring 22–28 years in healthcare commercial leadership, including CCO or portfolio authority across payers, provider networks or patient-access services. Your evidence includes contract remediation, provider capacity, pricing and regulated cross-border growth.

Candidates must show a commitment they limited or renegotiated when delivery evidence failed. Swiss healthcare and multilingual market exposure are valued. The permanent hybrid role is based in Zurich with substantial payer and provider engagement.

Compensation and terms

Base compensation is CHF 500,000–700,000 plus annual incentive and long-term participation linked to delivered access, contribution, contract quality, provider capacity and succession. The permanent hybrid Zurich appointment reports to the Group Chief Executive or nominated executive-committee sponsor. Replacement is urgent during active contract decisions.

Confidentiality

The organisation, patients, payers, providers, contracts, prices, networks and transition plans remain confidential. Further information follows conflict review and signed confidentiality. Applicants must not approach market participants to infer the client.